达托霉素治疗肠球菌血流感染:药效学分析提示应改变折点
该研究汇总观察性研究数据,分析达托霉素单药治疗肠球菌血流感染患者的药效学目标。114例患者中30天存活67例(58.8%),在低危患者中fAUC/MIC>27.43与生存相关。蒙特卡洛模拟显示当MIC=4 mg/L时6 mg/kg/day剂量的目标 attainment 概率仅1.5%-5.5%,提示现行折点可能不合理。
要点
- 低危肠球菌血流感染患者中,达托霉素fAUC/MIC>27.43与30天生存独立相关。
- MIC=4 mg/L时6 mg/kg/day剂量的目标 attainment 概率仅1.5%-5.5%。
- MIC=1 mg/L时相同剂量的目标 attainment 概率为91.0%-97.9%,提示折点应重新评估。
核心结论
- 在低危肠球菌血流感染患者中,达托霉素fAUC/MIC>27.43与30天生存相关。
- 现行批准剂量的药效学仅在MIC≤1 mg/L时达到优化,提示应重新评估敏感性折点。
研究设计与样本
- 汇总观察性研究数据,纳入接受达托霉素单药治疗的肠球菌血流感染患者114例。
- 排除治疗期间加用其他抗肠球菌抗生素和/或β-内酰胺类抗生素的患者。
- 采用已发表的人群药代动力学模型计算达托霉素暴露,通过分类回归树分析确定fAUC/MIC阈值并用多因素logistic回归确认,蒙特卡洛模拟计算目标 attainment 概率。
主要发现
- 114例接受达托霉素单药治疗的患者中,67例(58.8%)在30天时存活。
- 在低危患者(n=77)中,fAUC/MIC>27.43与生存相关(68.9% vs 37.5%,P=.006),调整感染来源和免疫抑制后仍显著(P=.026)。
- 当MIC=4 mg/L时,6 mg/kg/day(每24小时)剂量的目标 attainment 概率为1.5%-5.5%;当MIC=1 mg/L时为91.0%-97.9%。
关键数值与推荐
- 达托霉素对肠球菌的敏感性折点为MIC≤4 mg/L。
- 低危患者中与30天生存相关的fAUC/MIC阈值为>27.43。
- 6 mg/kg/day剂量在MIC=4 mg/L时目标 attainment 概率仅1.5%-5.5%,在MIC=1 mg/L时为91.0%-97.9%。
临床怎么用
- 对低危肠球菌血流感染患者,可参考fAUC/MIC>27.43的药效学目标优化达托霉素给药。
- 当MIC为4 mg/L时,6 mg/kg/day剂量的目标 attainment 概率极低,需考虑调整剂量或换药。
- 临床应关注达托霉素对肠球菌的敏感性折点是否需要修订。
局限性
- 研究基于观察性研究数据的汇总分析,非随机对照试验。
- 药效学阈值仅在低危患者中验证,未在高危患者中确认。
- 达托霉素暴露通过人群药代动力学模型计算,非个体化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie, minimum inhibitory concentration [MIC] ≤4 mg/L) is appropriate. In bacteremia, observational data support prescription of high doses (>8 mg/kg). However, pharmacodynamic targets associated with positive patient outcomes are undefined. METHODS: Data were pooled from observational studies that assessed outcomes in daptomycin-treated enterococcal bacteremia. Patients who received an additional antienterococcal antibiotic and/or a β-lactam antibiotic at any time during treatment were excluded. Daptomycin exposures were calculated using a published population pharmacokinetic model. The free drug area under the concentration-time curve to MIC ratio (fAUC/MIC) threshold predictive of survival at 30 days was identified by classification and regression tree analysis and confirmed with multivariable logistic regression. Monte Carlo simulations determined the probability of target attainment (PTA) at clinically relevant MICs. RESULTS: Of 114 patients who received daptomycin monotherapy, 67 (58.8%) were alive at 30 days. A fAUC/MIC >27.43 was associated with survival in low-acuity (n = 77) patients (68.9 vs 37.5%, P = .006), which remained significant after adjusting for infection source and immunosuppression (P = .026). The PTA for a 6-mg/kg/day (every 24 hours) dose was 1.5%-5.5% when the MIC was 4 mg/L (ie, daptomycin-susceptible) and 91.0%-97.9% when the MIC was 1 mg/L. CONCLUSIONS: For enterococcal bacteremia, a daptomycin fAUC/MIC >27.43 was associated with 30-day survival among low-acuity patients. As pharmacodynamics for the approved dose are optimized only when MIC ≤1 mg/L, these data continue to stress the importance of reevaluation of the susceptibility breakpoint.
引用
- Avery LM, Kuti JL, Weisser M, et al. Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clin Infect Dis. 2019. PMID: 30188976. doi:10.1093/cid/ciy749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。